



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail: hrm@gtbl.in.net

GTBL/BSE/NSE/2025-26/34

10th November, 2025

The Manager
Corporate Relationship Department
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Meeting Commencement time : 11: 00 A.M.
Meeting Conclusion Time : 03.00 P.M.

The Board of Directors at its meeting held today, have inter alia, transacted the following items of businesses:

- a) Approved the Unaudited Financial Results for the Quarter and Half year ended 30th September, 2025 along with the Limited Review Report issued by M/s. GMJ & Co., Chartered Accountants which are attached herewith.
- b) The Board on the recommendation of the Nomination & Remuneration Committee, has approved the appointment of Mr. Rajneesh Anand (DIN: 00134856) as an Additional Non-Executive Non-Independent Director of the Company for a period of 5 (Five) years with effect from 10th November, 2025 subject to the approval of members.

Further, the composition of Stakeholders Relationship Committee (SRC) and Corporate Social Responsibility (CSR) Committee of the Company have been reconstituted with the induction of Mr. Rajneesh Anand with effect from 10th November 2025.

The details of appointment are provided in **Annexure - A**

We request you to take the above on record please.

Thanking you,

Yours faithfully,

For Gujarat Themis Biosyn Limited

Vineet Gawankar
Company Secretary & Compliance Officer



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hbm@gtbl.in

Annexure - A

Disclosure under sub-para (7) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


1. Appointment of Mr. Rajneesh Anand (DIN:00134856) as an Additional Non-Executive Non-Independent Director of the Company:

Sr. No	Particulars	Details of Change
1.	Reason for change	Appointment as an Additional Non-Executive Non-Independent Director of the Company for a period of 5 (Five) years with effect from 10 th November, 2025.
2.	Date of Appointment	10 th November, 2025.
3.	Brief Profile	Mr. Rajneesh Anand is a graduate in Mechanical Engineering from M.S. University, Baroda, and is a postgraduate in Management from Jamnalal Bajaj Institute. He is a certified Chartered Engineer. He has been associated with Themis Group since 1977. He is the Director of Themis Medicare Limited and CEO & Director of Richter Themis Medicare (I) Pvt. Limited, the joint venture between Gedeon Richter Ltd. and Themis Medicare Limited in India.
4.	Disclosure of relationship between Directors (in case of appointment)	Not related to any of the Directors of the Company
5.	Affirmation	Mr. Rajneesh Anand is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. He has not been convicted of any offence in connection with the promotion, formation or management of any Company or LLP, nor found guilty of any fraud, misfeasance or breach of duty to any Company under the Companies Act, 2013 or any previous Companies Act in the last five years.

GUJARAT THEMIS BIOSYN LIMITED
CIN: L24230GJ1981PLC004878
69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat
Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025

Sr. No.	PARTICULARS	(Amount in INR Lakhs)					
		Quarter Ended			Half Year		Year Ended
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
I	Income from operations	4,234.88	3,587.28	3,471.65	7,822.16	7,354.39	15,079.99
II	Other Income	81.63	27.44	31.88	109.08	84.31	243.24
III	Total Income (I+II)	4,316.51	3,614.72	3,503.53	7,931.23	7,438.70	15,323.23
IV	Expenditure						
	(a) Cost of raw material consumed	692.39	682.59	620.93	1,374.98	1,237.18	2,577.72
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-	(153.06)	(19.88)	(96.50)	(172.94)	(108.61)	(127.23)
	(d) Employee benefits expense	484.78	311.19	328.43	795.98	648.06	1,264.11
	(e) Finance Cost	4.04	4.21	8.25	8.25	14.80	36.40
	(f) Depreciation and Amortisation expenses	295.90	203.38	143.55	499.28	258.35	537.49
	(g) Other Expenses	-	-	-	-	-	-
	i) Stores and spares	204.19	136.98	163.77	341.16	338.26	737.32
	ii) Power	541.41	517.66	495.29	1,059.07	981.26	1,997.36
	iii) Fuel	126.97	146.67	155.54	273.65	278.46	563.90
	iv) Water	25.49	28.60	22.82	54.09	48.82	102.21
	v) Other expenditure	218.34	391.36	242.31	609.70	536.96	1,080.16
	Total Expenses	2,440.46	2,402.76	2,084.39	4,843.21	4,233.53	8,769.44
V	Profit/(Loss) before Exceptional Items and Tax (III-IV)	1,876.05	1,211.96	1,419.14	3,088.02	3,205.17	6,553.79
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(Loss) before Tax (V-VI)	1,876.05	1,211.96	1,419.14	3,088.02	3,205.17	6,553.79
VIII	Tax expenses						
	(a) Current Tax	308.31	246.64	361.71	554.96	818.86	1,669.61
	(b) Deferred Tax	141.34	59.16	0.78	200.50	6.05	28.05
	(c) Income Tax of earlier years	-	-	-	-	-	(21.05)
IX	Net Profit/(Loss) after tax (VII-VIII)	1,426.40	906.16	1,056.64	2,332.57	2,380.26	4,877.17
X	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss						
	(i) remeasurement of defined benefit plans;	1.70	1.70	11.27	3.40	10.20	6.81
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	(0.43)	(0.43)	(2.84)	(0.86)	(2.57)	(1.71)
XI	Total Comprehensive Income for the period (IX+X)	1,427.67	907.44	1,065.07	2,335.11	2,387.90	4,882.26
XII	Paid-up equity share capital	1,089.65	1,089.65	1,089.65	1,089.65	1,089.65	1,089.65
XIII	Other Equity						23,748.54
XIV	Earnings Per Share (Basic and Diluted)	1.31	0.83	0.97	2.14	2.18	4.48




Notes:

- 1 The financial results for the quarter and year ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 10, 2025.
- 2 The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 The Company has completed the expansion of its Fermentation Block at its manufacturing facilities at Vapi, Gujarat. The first batch of commercial production of Rifamycin-S and Rifamycin-O commenced on Saturday, October 18, 2025. With this expansion, the overall fermentation capacity of the Company has increased from 450 KL to 990 KL. This will further strengthen the Company's manufacturing capabilities to produce multiple fermentation products. With this capacity expansion, the Company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment.
- 5 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

Place: Mumbai
Date : November 10, 2025

For GUJARAT THEMIS BIOSYN LIMITED


Dr. DINESH PATEL
Chairman
DIN : 00033273



GUJARAT THEMIS BIOSYN LIMITED
BALANCE SHEET AS AT SEPTEMBER 30, 2025

(Amount in INR Lakhs)



Particulars	Note No.	As at September 30, 2025	As at March 31, 2025
ASSETS			
Non-Current Assets			
(a) Property, Plant and Equipment	4	15,935.74	4,058.01
(b) Capital Work-in-Progress	4	13,230.38	18,440.82
(c) Right-of-use Assets	4(a)	263.25	54.94
(d) Other Intangible Assets	4(b)	12.73	15.91
(e) Financial Assets			
(i) Loans	5	75.00	75.00
(ii) Other Financial Assets	5	90.05	161.87
(f) Other Non-Current Assets	10	2,579.63	2,127.41
Total Non-Current Assets		32,186.78	24,933.94
Current Assets			
(a) Inventories	6	721.15	504.61
(b) Financial Assets			
(i) Trade Receivables	7	3,513.75	3,123.82
(ii) Cash and Cash Equivalents	8	635.62	1,169.39
(iii) Bank Balances other than (ii) above	9	372.41	85.42
(iv) Loans	5	0.85	0.35
(v) Other Financial Assets	5	30.30	99.44
(c) Other Current Assets	10	206.33	214.28
Total Current Assets		5,480.41	5,197.31
TOTAL ASSETS		37,667.19	30,131.25
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share capital	12	1,089.65	1,089.65
(b) Other Equity	13	25,353.59	23,748.54
Total Equity		26,443.24	24,838.20
Liabilities			
(A) Non Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	14	6,870.00	2,963.60
(ia) Lease liabilities	14(a)	133.05	-
(b) Provisions	18	84.80	77.28
(c) Deferred Tax liabilities (Net)	11	396.71	196.21
Total Non-Current Liabilities		7,484.56	3,237.09
(B) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	14	25.96	25.39
(ia) Lease liabilities	14(a)	120.15	57.97
(ii) Trade Payables	16		
-Total outstanding dues of Micro enterprises and Small enterprises		58.84	65.36
-Total outstanding dues of creditors other than micro enterprises and small enterprises		2,917.05	1,399.60
(iii) Other Financial Liabilities	15	417.98	428.44
(b) Other Current Liabilities	17	168.35	50.89
(c) Provisions	18	31.06	28.32
(d) Current Tax Liabilities (Net)	19	-	-
Total Current Liabilities		3,739.39	2,055.97
TOTAL EQUITY AND LIABILITIES		37,667.19	30,131.25



GUJARAT THEMIS BIOSYN LIMITED
CIN: L24230GJ1981PLC004878
69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat
Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED SEPTEMBER 30, 2025

Particulars	(Amount in INR Lakhs)	
	Year ended September 30, 2025 (Unaudited)	Year ended March 31, 2025 (Audited)
CASH FLOWS FROM OPERATING ACTIVITIES:		
Profit before tax	3,088.02	6,553.79
Adjustments for:		
Depreciation and amortisation expense	499.28	565.24
Interest income classified as investing cash flows	(19.99)	(63.84)
Sundry balance written back	(10.00)	(11.34)
Interest income on Lease	(3.31)	(7.35)
Gain on lease termination	-	(11.88)
Foreign exchange fluctuation gain	-	(5.34)
Finance costs	8.25	43.91
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables	(389.93)	(421.27)
(Increase)/Decrease in inventories	(216.54)	(171.94)
Increase/(Decrease) in trade payables	1,510.93	83.34
(Increase)/ Decrease in other financial assets	490.55	5,079.22
(Increase)/Decrease in other assets	(337.26)	(1,424.03)
Increase/(Decrease) in provisions	13.67	479.45
(Increase)/Decrease in Other bank balance	(286.99)	105.70
Increase/(Decrease) in other financial liabilities	(10.46)	12.61
Increase/(Decrease) in other current liabilities	117.46	(54.83)
Cash generated from operations	4,453.68	10,751.43
Less: Income taxes paid (Net)	(661.97)	(1,648.57)
Net cash inflow from operating activities	3,791.71	9,102.86
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for property, plant and equipment	(7,272.85)	(11,615.02)
Receipts from repayment of loans given to other parties	(0.50)	(0.12)
Interest received	16.07	433.33
Net cash outflow from investing activities	(7,257.28)	(11,181.82)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from Borrowings(Net of repayment)	3,906.97	2,988.99
Dividend paid	(730.07)	(181.67)
Repayment of Lease Liability	(65.04)	(163.11)
Interest paid	(180.06)	(42.79)
Net cash inflow (outflow) from financing activities	2,931.80	2,601.43
Net increase (decrease) in cash and cash equivalents	(533.76)	522.47
Cash and Cash Equivalents at the beginning of the financial year	1,169.39	646.92
Cash and Cash Equivalents at end of the year	635.62	1,169.39
Cash and cash equivalents as per above comprise of the following:		
Balances with banks	589.31	197.85
Cash on hand	0.31	0.29
Bank Deposits with less than 3 months maturity	46.00	971.25
Balances as per statement of cash flows	635.62	1,169.39

Independent Auditor's Review report on Quarterly Unaudited Financial Results and Year to Date Results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Review report to
The Board of Directors
GUJARAT THEMIS BIOSYN LIMITED**

We have reviewed the accompanying statement of Unaudited financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended September 30, 2025 and year to date from April 1, 2025 to September 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GMJ & Co

Chartered Accountants

FRN: 103429W



CA Amit Maheshwari

Partner

M. No.: 428706

UDIN: 254287 06BMIP CH3829



Place : Mumbai

Date : November 10, 2025